Share
FDA Approval of the Joint Biological Agent Identification and Diagnostic System: Implications for the Future (in English)
Carol C. Walters
(Author)
·
Biblioscholar
· Paperback
FDA Approval of the Joint Biological Agent Identification and Diagnostic System: Implications for the Future (in English) - Walters, Carol C.
$ 48.80
$ 57.95
You save: $ 9.15
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My WishlistsIt will be shipped from our warehouse between
Monday, July 01 and
Tuesday, July 02.
You will receive it anywhere in United States between 1 and 3 business days after shipment.
Synopsis "FDA Approval of the Joint Biological Agent Identification and Diagnostic System: Implications for the Future (in English)"
In 1999 the AF Medical Service (AFMS) successfully field-tested its first deployable biowarfare (BW) agent testing capability, and by early 2001 had created twelve deployable Biological Augmentation Teams. These teams were trained to use the blossoming technology of polymerase chain reaction (PCR) in detecting four BW agents within a matter of hours. This was revolutionary, as traditional microbiological techniques took from 18 hours to days to produce a result. Even more exciting was the fact that a "delicate" technology such as PCR could be ruggedized and perform successfully in a deployed environment. Since those first steps in 1999, the AFMS has come a long way in fielded BW agent testing capability. Over these seven seemingly long years, the BW testing systems have steadily improved, to the point that a jointly acquired system is now being fielded for testing ten BW agents.
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.
✓ Producto agregado correctamente al carro, Ir a Pagar.
